

Research

Open Access

Large-scale functional expression of WT and truncated human adenosine A_{2A} receptor in *Pichia pastoris* bioreactor cultures

Shweta Singh^{†1}, Adrien Gras^{†1}, Cédric Fiez-Vandal^{2,4}, Jonathan Ruprecht¹, Rohini Rana¹, Magdalena Martinez¹, Philip G Strange³, Renaud Wagner² and Bernadette Byrne^{*1}

Address: ¹Membrane Protein Crystallography Group, Division of Molecular Biosciences, Imperial College London, South Kensington, London, SW7 2AZ, UK, ²Unité Mixte de Recherche 7175 École Supérieure de Biotechnologie de Strasbourg – Centre National de la Recherche Scientifique, Département Récepteurs et Protéines Membranaires, 67412 Illkirch, France, ³School of Pharmacy, PO Box 228, University of Reading, Whiteknights, Reading RG6 6AJ, UK and ⁴Karolinska Institutet, Department of Medical Biochemistry and Biophysics (MBB), Division of Biophysics, Scheeles väg 2, 171 77 Stockholm, Sweden

Email: Shweta Singh - s.singh06@imperial.ac.uk; Adrien Gras - adrien.gras04@imperial.ac.uk; Cédric Fiez-Vandal - Cedric.Fiez-Vandal@ki.se; Jonathan Ruprecht - j.ruprecht@imperial.ac.uk; Rohini Rana - r.rana06@imperial.ac.uk; Magdalena Martinez - magdalena.martinez@imperial.ac.uk; Philip G Strange - p.g.strange@reading.ac.uk; Renaud Wagner - rwagner@esbs.u-strasbg.fr; Bernadette Byrne* - b.byrne@imperial.ac.uk

* Corresponding author †Equal contributors

Published: 10 October 2008

Received: 28 August 2008

Microbial Cell Factories 2008, **7**:28 doi:10.1186/1475-2859-7-28

Accepted: 10 October 2008

This article is available from: <http://www.microbialcellfactories.com/content/7/1/28>

© 2008 Singh et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The large-scale production of G-protein coupled receptors (GPCRs) for functional and structural studies remains a challenge. Recent successes have been made in the expression of a range of GPCRs using *Pichia pastoris* as an expression host. *P. pastoris* has a number of advantages over other expression systems including ability to post-translationally modify expressed proteins, relative low cost for production and ability to grow to very high cell densities. Several previous studies have described the expression of GPCRs in *P. pastoris* using shaker flasks, which allow culturing of small volumes (500 ml) with moderate cell densities (OD₆₀₀ ~15). The use of bioreactors, which allow straightforward culturing of large volumes, together with optimal control of growth parameters including pH and dissolved oxygen to maximise cell densities and expression of the target receptors, are an attractive alternative. The aim of this study was to compare the levels of expression of the human Adenosine 2A receptor (A_{2A}R) in *P. pastoris* under control of a methanol-inducible promoter in both flask and bioreactor cultures.

Results: Bioreactor cultures yielded an approximately five times increase in cell density (OD₆₀₀ ~75) compared to flask cultures prior to induction and a doubling in functional expression level per mg of membrane protein, representing a significant optimisation. Furthermore, analysis of a C-terminally truncated A_{2A}R, terminating at residue V334 yielded the highest levels (200 pmol/mg) so far reported for expression of this receptor in *P. pastoris*. This truncated form of the receptor was also revealed to be resistant to C-terminal degradation in contrast to the WT A_{2A}R, and therefore more suitable for further functional and structural studies.

Conclusion: Large-scale expression of the A_{2A}R in *P. pastoris* bioreactor cultures results in significant increases in functional expression compared to traditional flask cultures.

Background

G-protein-coupled receptors (GPCRs) form a large superfamily of cell-surface receptors that mediate cellular responses to a wide range of biologically active molecules including hormones, neurotransmitters and drugs. Indeed, half of all currently available pharmaceuticals act through GPCRs [1,2]. The physiological and pharmacological importance of these proteins makes them key targets for drug discovery programmes. Our understanding of the precise mechanism of action of these important proteins is currently limited by a lack of high-resolution structural data. One limiting factor to structural studies of GPCRs has, until recently, been low expression levels [3]. With the exception of rhodopsin, all GPCRs are expressed at very low levels endogenously, thus requiring the development of recombinant overexpression systems. Careful expression vector design, GPCR codon-optimisation [4] and high throughput approaches used to identify GPCRs with the highest expression levels in different expression systems [5] are among the methods that have been used to produce sufficiently high levels of functional GPCRs suitable for structural studies.

Success has been achieved when using the expression host *Pichia pastoris* for the production of membrane proteins for structural studies, most notably the rat membrane protein K⁺ channel [6]. *Pichia* has several advantages over other systems for the production of GPCRs. It is easy to manipulate, has high production levels and is relatively inexpensive. In addition, *Pichia* has the ability to glycosylate expressed receptors, albeit in a modified form compared to higher eukaryotes, which is essential for the proper functioning and membrane targeting of many receptors [7-10]. Much effort has been applied to the optimisation of *Pichia* expression systems specifically for GPCR production [11-16]. The basic system uses a pPIC9K vector (Invitrogen) where GPCR expression is under the control of the strong methanol inducible AOX1 promoter. Protease deficient expression strains, such as the SMD1163 strain, and the use of the α -factor leader sequence have improved receptor expression levels [11,12]. Modifications to the growth media including addition of histidine, receptor specific ligands and dimethyl sulfoxide, which facilitates phospholipid biosynthesis and membrane proliferation in yeast [17] have been shown to increase the expression levels of 20 different GPCRs in *Pichia* [15]

An additional advantage to the use of *Pichia* is that it readily adapts to large-scale culture in bioreactors [18]. Bioreactors allow precise regulation of the aeration, pH and addition of carbon source, which in turn allows the cultures to grow to ultra-high cell densities maximising expression of the target protein. However optimisation of standard protocols is usually necessary for specific targets.

One particular issue is the amount of methanol added for induction. Indeed, very high levels of methanol can induce cytotoxic effects which reduce cell viability and thus expression [19]. Methanol sensors, which detect the level of unmetabolised methanol have been key to reducing these cytotoxic effects. Another important issue to consider is the osmotic stress induced during high cell density culturing which is known to be responsible for adaptive cell response mechanisms, such as changes in the membrane lipid content [20]. This may not be desirable in the process of membrane protein production and medium cell density culturing approach may appear more suitable. One aim of this study was to develop a protocol for the large scale expression of GPCRs in *P. pastoris* using bioreactors. The target GPCR used for development and characterisation of the protocol was the human Adenosine A_{2A} receptor (A_{2A}R), one of four receptors mediating the effects of adenosine. The A_{2A}R is key in downregulation of immune responses *in vivo* and this in turn prevents inflammatory damage of healthy tissue [21]. In addition, it has been implicated in several serious conditions including cancer, Parkinson's disease and asthma. A number of studies have previously shown heterologous expression of this receptor in a range of expression hosts including *Escherichia coli* [22], *Pichia pastoris* [16] and *Saccharomyces cerevisiae* [23]. The A_{2A}R expressed in *E. coli* was sensitive to C-terminal proteolysis upon solubilisation [22]. Recent studies have shown the importance of removal of the unstructured C-terminal tail, among other modifications, in obtaining well diffracting crystals and ultimately structure determination of GPCRs [24,25]. The A_{2A}R has a particularly long C-terminal tail, comprised of approximately 96 amino acid residues, likely to reduce the chances of obtaining well diffracting crystals. Therefore we also wished to assess the effects of generating a C-terminal truncation on the functional expression and stability of the receptor. A receptor construct was generated truncating the protein at valine 334 (V334), a residue corresponding to the end of the rhodopsin C-terminal tail.

Using a previously described vector system [15] for expression we have developed a large-scale fermentation protocol which produces significantly higher levels of functional A_{2A}R than the equivalent volume of culture using published shaker flask protocols [15,16]. This study has also identified a C-terminally truncated version of the A_{2A}R receptor which is more highly expressed and more stable than the WT. This construct may be more suitable for downstream functional and structural studies.

Methods

Materials

Yeast nitrogen base and yeast extract were purchased from Difco, peptone and L-histidine from Sigma-Aldrich and dimethyl sulfoxide (DMSO) from Acros Organics. Com-

plete EDTA-free protease inhibitor cocktail tablets were purchased from Roche and the bicinchoninic acid assay (BCA) kit purchased from Pierce. Scintillation cocktail (Ultima Gold MV) was obtained from PerkinElmer. [³H] ZM 241385 was obtained from American Radiolabelled Chemicals Inc. while ZM241385 was obtained from Tocris and Theophylline from Fisher Scientific. Nitrocellulose membrane was obtained from Millipore and GF/B filters were from Whatman. The mouse M2 anti-FLAG antibody was from Sigma-Aldrich and the sheep anti-mouse IgG-horseradish peroxidase (HRP) conjugate from GE Healthcare. All other chemicals were obtained from Sigma-Aldrich.

Expression constructs

The WT A_{2A}R was expressed using a modified pPIC9K (Invitrogen) vector incorporating a Flag tag followed by a 10 His tag and a TEV cleavage site all upstream of the gene coding for the receptor as described by Andre et al, [15]. This vector was further modified to remove the Bio-tag located downstream of the gene coding for the receptor. The forward primer 5'-GGT GGA TCC ATG CCC ATC ATG GGC TCC TCG GTG TAC-3' together with the reverse primer 5'-CAT GGA ATT CAC TAG TGA CCT GCT CTC CGT CAC TGC CAT GAG CTG CCA AG-3' introducing a stop codon after residue V334 was used to amplify the truncated A_{2A}R gene fragment. This amplified gene fragment was sequenced and cloned into the *Bam*HI and *Spe*I restriction sites of the modified pPIC9K (Invitrogen) vector. Expression plasmids were transformed by electroporation into SMD1163 *P. pastoris* cells.

Small scale cultures

Single *P. pastoris* colonies containing the plasmid of interest were selected on YPD plates [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose, 2% (w/v) agar] containing 0.25% geneticin. Cells from a single colony were used to inoculate 5 ml of BMGY medium [100 mM potassium phosphate pH 6.0, 1% (w/v) yeast extract, 2% (w/v) peptone, 1.34% (w/v) yeast nitrogen base without amino acids, 0.0004% (w/v) biotin, 1% (w/v) glycerol]. The culture was grown overnight at 30°C to an OD₆₀₀ of 12–15. The cells were spun down at 3,000 g for 5 min and the cell pellet was resuspended in typically 10 ml BMMY [similar to BMGY with the following changes: phosphate buffer at pH 8.0, 2.5% (v/v) dimethyl sulfoxide, 0.04% (w/v) histidine, and 0.5% (v/v) methanol instead of 1% glycerol] to achieve a starting OD₆₀₀ of 5 for all cultures. The culture was incubated for 18 h at 22°C and then the cells harvested by centrifugation at 5000 g for 5 mins. The highest expressing clones were selected by Western blot for further study.

Flask cultures

Single *P. pastoris* colonies from high expressing clone were selected on YPD plates containing 0.25% geneticin. Cells from a single colony were used to inoculate 50 ml of BMGY medium. The culture was grown overnight at 30°C to an OD₆₀₀ of 3–5. A total of 500 ml of BMGY was inoculated with 25 ml of the starter culture and grown for 6–8 h to an OD₆₀₀ of 5–10. The cells were spun down at 3,000 g for 20 min and the cell pellet was resuspended in 500 ml BMMY. The culture was incubated for 20 h at 22°C and then the cells harvested by centrifugation. Samples (1 ml) were taken at various time points during expression (0, 4, 14, 16, 18, 20 hours post induction). The cells were harvested and stored at -80°C for further analysis.

Bioreactor cultures

Single *P. pastoris* colonies containing the plasmid of interest were selected on YPD plates containing 0.25% geneticin. Cells from a single colony were used to inoculate a 150 ml (or 500 ml for inoculation of a 20 L bioreactor vessel) starter culture of MGY medium (0.1 M potassium phosphate pH 6, 1.34% yeast nitrogen base, 0.0004% biotin, 1% glycerol). The culture was grown at 30°C with aeration for 18–22 hours to an OD₆₀₀ ~10–15. The entire inoculum was added to a 5 L fermenter vessel at t = 0. Cultures were grown in a 5 L bioreactor vessel controlled by an ADI 1010 bio-controller connected to a PC running BioExpert software (all from Applikon Biotechnology). A methanol sensor (Raven Biotech) was used to monitor and control methanol levels in the vessel. The internal regulation software of the sensor was used to control the external peristaltic pump and adjust methanol concentration to the set point. Agitation was set at 1000 rpm, pH at 5.0 and dO₂ at 35% for the entire run. For the initial cell growth phase the temperature was set at 30°C. In this initial phase, the culture was allowed to consume all the glycerol contained in the 4 L of FM22 culture medium (4.3% (w/v) monobasic potassium phosphate, 0.5% (w/v) ammonium sulphate, 0.1% (w/v) calcium sulphate, 1.43% (w/v) potassium sulphate, 1.17% (w/v) magnesium sulphate) containing 2% (w/v) glycerol and 1 ml/L PMT4 trace elements solution (0.2% (w/v) copper sulphate, 0.008% (w/v) sodium iodide, 0.3% (w/v) manganese sulphate, 0.02% (w/v) sodium molybdate, 0.002% (w/v) boric acid, 0.05% (w/v) calcium sulphate, 0.05% (w/v) cobalt chloride, 0.7% (w/v) zinc chloride, 2.2% (w/v) iron sulphate, 0.02% (w/v) biotin, 1 ml/L sulphuric acid). During a second growth phase the culture was fed 50% glycerol at a rate of 3.5 ml/L/h until the OD₆₀₀ reached approximately 75 (~3–4 h). The temperature of the vessel was then reduced to 22°C and the cells treated with a 0.1% v/v aliquot of 100% methanol supplemented with 4 ml/L PMT4, 3% DMSO, 0.04% histidine and the methanol sensor signal allowed to stabilise. The signal output was recorded in mV and the methanol feed-

ing system set point was set to this value. The culture was allowed to adapt to 0.1% methanol for 5 h. For the induction stage, the methanol concentration was raised to 0.5% v/v in steps of 0.1% v/v every 2 to 3 hours. At the end of the induction period (~18 h) the cells were harvested by centrifugation at 3,000 g for 5 min. Samples (1 ml) were taken at various time points during the culture (6, 4 and 2 hours pre induction and 0, 3, 6, 9, 12, 15, 18, and 21 hours post induction). The cells were harvested and stored at -80°C for further analysis.

Membrane preparation

Cells were resuspended in ice-cold breaking buffer (50 mM HEPES-NaOH pH 7.4, 100 mM NaCl, 10% (w/v) glycerol, 2 mM EDTA, 1 mM PMSF, 300 nM ZM241385, (1/100 ml) PI), and broken using a tissue lyser (Qiagen) set to 30 MHz for 15 mins. Cell debris, including intact cells, were removed by a low speed spin (3,000 g) for 10 min. The supernatant was retained, and membranes isolated by centrifugation at 100,000 g for 30 min. Each membrane pellet was re-dissolved in a membrane buffer (50 mM HEPES-NaOH pH 7.4, 100 mM NaCl, 10% (w/v) glycerol) and flash frozen in liquid nitrogen for storage.

Radioligand binding assays

All radioligand binding assays were performed using the A_{2A}R antagonist [³H] ZM241385 in binding buffer (20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1% BSA, pH 7.4). Single-point binding assays on yeast membrane-bound receptor contained 2 µg of membrane protein in a final volume of 1 ml in the presence of a saturating concentration (4 nM) of radioligand at 25°C for 3 hours. Non-specific binding was determined in the presence of 10 mM theophylline, an A_{2A}R antagonist and for each time-point the assay was performed in triplicate. Following incubation, bound and free radioligands were separated on Whatman GF/B filters using a cell harvester (Brandel). The filters were washed three times with ice-cold phosphate buffered saline, and the amount of bound radiolabel assessed using a LS 6500 scintillation counter (Beckman Coulter). Binding data were analysed by non-linear least squares fitting using the computer package GraphPad Prism.

Protein concentration

All protein concentrations were determined by Lowry assay using bovine serum albumin as standard [26].

SDS-PAGE and Western blotting

For Western-blot analysis the proteins were separated on a 4–12% Bis-Tris NuPAGE gel prior to transfer to a PVDF membrane using the X-Cell system (Invitrogen). The blot was probed with 1:10,000 dilution of primary anti-FLAG M2 (Sigma) antibody followed by a 1:10,000 dilution of secondary goat anti-mouse horseradish peroxidase anti-

body. Protein bands were visualised using ECL substrate (GE Biosciences).

Results

Bioreactors allow controlled cell growth

Figure 1 shows the changes in two parameters: dissolved oxygen (dO₂) and OD₆₀₀ during a sample bioreactor culture for both WT A_{2A}R (A) and V334 A_{2A}R (B) constructs. The initial glycerol batch phase (phase 1) showed a gradual decrease in dissolved oxygen (dO₂) levels followed by a stabilisation at 35%, the configured set point. As the cells multiply and consume glycerol, the culture's requirement for oxygen increased, lowering the observed dO₂ in the vessel. Once the 35% set point was reached, the system maintained dO₂ levels by modulating the airflow. This ensured the culture did not starve of oxygen until all the batch glycerol was exhausted. This phase lasted approximately 22 hours with minor differences depending on the OD₆₀₀ of the starting inoculum. A sharp rise in dO₂ after ~19 h cultivation indicated that the cells were starving for glycerol and did not require oxygen to metabolise the carbon source. The glycerol fed-batch phase (phase 2 on Figure 1) was then initiated. The culture was fed 50% glycerol at 3.5 ml/L/hour until the OD₆₀₀ reached approximately 75. This caused dO₂ levels to drop and stabilise again at 35%. This phase lasted between 3 and 4 hours. The culture was then allowed to consume any remaining glycerol before the start of the induction phase. Protein expression was induced by the addition of methanol. An adaptation period of 3–5 hours was required during which the cells alter their metabolism to accept methanol as the new carbon source. This was observed as a steady decrease in dO₂ levels as the cells slowly adapt to methanol utilisation. During this phase the OD₆₀₀ remained relatively stable at about 75 for the WT A_{2A}R construct while typically a small increase was observed for the V334 A_{2A}R (from 75 to ~80). The highly similar dO₂ and OD₆₀₀ traces for the two different constructs demonstrate the reproducibility of the bioreactor culture protocol described in this study.

Western blot analysis of WT A_{2A}R and V334 A_{2A}R expressed in flask and bioreactor cultures

Expression of the two different receptors during the induction phase for both flask and bioreactor cultures was monitored using both Western blot analysis and radioligand binding assay. Western blot analysis of flask cultures expressing WT A_{2A}R showed a gradual increase in expression over the course of the induction phase with receptor protein first detectable at 14 hours post induction (Figure 2A) as a band of approximately 38 kDa. Several larger bands are also visible. These are likely to be due to different oligomeric forms of the receptor formed as a result of gel running conditions rather than representing the true state of the receptor. Due to the large gap in sampling




Figure 1
Comparison of key bioreactor culture parameters. Changes in OD₆₀₀ (dashed line) and dissolved oxygen (solid line) over time during the bioreactor culture of the (A) WT A_{2A}R and (B) V334 A_{2A}R are indicated. Time periods indicated by the numbers correspond to (1) glycerol batch phase (2) glycerol fed-batch phase and (3) methanol induction phase.




Figure 2
Expression of the A_{2A}R constructs over time. Western blot analysis of WT A_{2A}R (A) and V334 A_{2A}R (B) expressed in flask and WT A_{2A}R (C) and V334 A_{2A}R (D) in bioreactor cultures. Analysis was performed on membranes prepared from cells harvested at the different time points using anti-Flag antibody. M denotes the molecular weight markers and the numbers along the top of blots correspond to the time points.

times it is likely that receptor is expressed before 14 hours, however it is clear that no receptor is expressed at 4 hours post induction. The amount of WT $A_{2A}R$ did not seem to significantly increase after this. The V334 $A_{2A}R$ expressed in flasks (Figure 2B) was first detected as a band of approximately 28 kDa at a similar time point however the amount of protein increased significantly after this to the 20 hour time point where the culture was harvested. Expression of the WT $A_{2A}R$ in the bioreactor also increased with time although the expression was detectable by Western blot at 3 hrs in contrast to the flask cultures (Figure 2C). A similar trend is observed for the V334 $A_{2A}R$ (Figure 2D). There were some low molecular weight bands visible for the WT $A_{2A}R$, indicating that there is proteolytic degradation of the expressed receptor. The fact that these bands are being detected using the N-terminally positioned Flag tag suggests that the bands observed are due to C-terminal degradation. This is not observed in the flask culture for either construct, or the bioreactor culture expressing the V334 $A_{2A}R$. Interestingly however there is a distinctive band visible at ~ 45 kDa for the V334 $A_{2A}R$ bioreactor samples which is not present in the flask culture for the same construct. It is possible that the higher levels of expression detected for the V334 $A_{2A}R$ in the bioreactor stimulates a larger amount of dimer formation in the membrane.

Functional analysis of WT $A_{2A}R$ and V334 $A_{2A}R$ expressed in flask and bioreactor cultures

Radioligand binding analysis indicated a similar trend in increasing expression of functional receptor from the flask cultures. There was no measurable functional receptor for the first 4 hours post induction (Figure 3A) while after this time functional expression increased rapidly, as measured at 14 hours. In the case of the WT $A_{2A}R$ the expression level does not increase much after 14 hours with a final expression level of 23 pmol/mg. The $A_{2A}R$ V334 construct expresses to a much higher level after 14 hours (53 pmol/mg) and increases significantly after that to a final expression level of 72 pmol/mg after 20 hour (Figure 3A). The expression profile is slightly different in the case of the bioreactor cultures. Derepression of the methanol promoter due to depletion of the glycerol during the second growth phase, induces expression from the AOX1 promoter resulting in low level but measurable receptor production prior to induction. For both the WT $A_{2A}R$ and the V334 receptor constructs there is a steady increase in expression up to 6 hours post induction (Figure 3B). After this time the expression of the WT $A_{2A}R$ continues to increase steadily peaking at approximately 125 pmol/mg at the end of the culture (18 hrs) while $A_{2A}R$ V334 increases much faster peaking at 250 pmol/mg at 18 hrs (Figure 3B). The culture for the V334 construct was continued for a further 3 hours however the data suggests that this results in a slight drop in functional expression. It




Figure 3
Functional expression of the $A_{2A}R$ constructs over time. Radioligand binding analysis of both the WT $A_{2A}R$ (filled triangles) and V334 $A_{2A}R$ (filled circles) receptors expressed in flask (A) and bioreactor (B) cultures. Membranes prepared from cells harvested at the different time points were assessed using radioligand binding assay using [3H] ZM241385. Induction of the cultures was initiated by addition of methanol at time 0 hours. Data shown are representative of at least $n = 2$ experiments for each condition.

may be that 18 hrs is the optimal harvesting time for the bioreactor cultures.

Discussion

Flask versus bioreactor expression

The main aim of the study was to compare the expression of $A_{2A}R$ in flask and bioreactor based cultures. The flask conditions used in this study were similar to, or the same, as those which have previously been used for expression of the $A_{2A}R$ in *P. pastoris* [15,16]. Flask cultures enable the exploration of several expression conditions in parallel and require a limited set-up compared to bioreactor based cultures. However there are a number of drawbacks to flask cultures, which the bioreactor is particularly well suited to overcome. The principal advantage of the biore-

actor set up is that it enables large volumes of air to be circulated within the culture to satisfy the high oxygenation requirements of *P. pastoris* cultivation to high OD₆₀₀. The ability to regulate pH and dissolved oxygen (dO₂) was shown to greatly improve batch-to-batch reproducibility while glycerol and methanol feeding lines enable accurate control over the amount of nutrients added to the culture. *P. pastoris* synthesises alcohol oxidase 1 (AOX1), which metabolises methanol by conversion to formaldehyde. However, if high concentrations of methanol are introduced without pre-conditioning of the culture to this carbon source, excess formaldehyde can accumulate to toxic levels to the cells [27]. It is therefore very important to allow the culture to adapt to methanol utilisation using low methanol concentration. Initial inductions performed in the absence of accurate methanol control systematically produced very erratic expression profiles (data not shown). The implementation of a methanol control system proved essential for the reliability and reproducibility of receptor expression.

The cell density achieved in the bioreactor cultures was routinely almost six times higher than that achieved in flask cultures as assessed by measurement of the OD₆₀₀. In addition radioligand binding indicated that there was an approximately three and a half times higher functional expression for the bioreactor culture compared to the flask culture (summarised in Table 1). Thus the expression level in the bioreactor is increased in two ways; 1) the biomass is increased and 2) the production of functional receptor is increased per mg of membrane protein. These data clearly demonstrate the high efficiency receptor production that can be achieved by the careful regulation and optimisation of the growth parameters possible in bioreactor cultures. It is likely that the protocol described here is suitable for large scale production of other GPCRs in bioreactors since increases in functional expression level have also been obtained for the human dopamine D2 and the human serotonin 5HT1D receptors compared to flask cultures (data not shown).

Protein expression in the absence of inducer, so-called leaky expression, is often observed when using recombinant systems [28]. The binding assay results indicated that in the case of both the WT and V334 A_{2A}R expressed in bioreactors, receptor was present prior to methanol

induction. Glycerol represses the AOX1 promoter used for A_{2A}R expression and therefore no receptor should be detected prior to the addition of methanol. However, as the culture is allowed to fully deplete the glycerol present in both glycerol batch and glycerol fed-batch phases, some degree of derepression can occur, allowing some protein to be synthesised. Ligand binding analysis also indicated the presence of small amounts of receptor (maximally ~25 pmol/mg) in bioreactor samples taken prior to induction with methanol. From published data, no more than 2–4% of the total attainable amount of AOX1 induced protein is normally produced through derepression [29]. Interestingly, according to our measurements, an estimated 10–15% receptor was produced in starvation conditions. Functional analysis of the receptor produced as a result of derepression indicates that A_{2A}R produced during derepression is correctly folded and functional. The relatively low OD₆₀₀ values achieved in flask cultures mean it is unlikely that all the glycerol is consumed in the glycerol batch phase explaining why no expression is detectable at induction (time = 0 hours) due to derepression of the AOX1 promoter.

WT A_{2A}R versus V334 A_{2A}R functional expression

Radioligand binding analysis indicated that higher levels of receptor were produced for the truncated V334 A_{2A}R compared to the WT A_{2A}R in both flask and bioreactor cultures with the V334 A_{2A}R expressing at approximately double the amount of the WT receptor (Table 1). The B_{max} value of 200 pmol/mg achieved for the V334 A_{2A}R is the highest reported value for functional expression of the A_{2A}R in *P. pastoris*. This is lower than that achieved for expression of the A_{2A}R in both *S. cerevisiae* (480 pmol/mg; [23]) and mammalian cells (287 pmol/mg; [30]). However the higher cell densities achieved using *P. pastoris* mean that higher expression levels per litre are obtained. Smaller bioreactors are required for *P. pastoris* growth than for *S. cerevisiae* making the cultures both cheaper and easier to handle.

Numerous studies have indicated that C-terminal truncation of GPCRs produces a much more stable protein, more suitable for structural studies [24,25]. Western blot analysis of the WT A_{2A}R expressed in the bioreactor indicated the presence of degradation bands likely to be the result of C-terminal degradation. This is a major concern

Table 1: Cell densities and specific binding for the A_{2A}R constructs expressed in flask and bioreactor cultures

Construct	Cell density (OD ₆₀₀)*		Maximum specific binding (pmol/mg)	
	Flask	Bioreactor	Flask	Bioreactor
WT A _{2A} R	14	75	32.5 ± 9.3	112.5 ± 2.7
A _{2A} R V334	14	80	82.9 ± 11.2	200.6 ± 17.6

* cell density at induction

since the His-tag to be used for immobilised metal affinity chromatography is N-terminally located. Thus, purification would not differentiate between intact and degraded receptor. In contrast the V334 A_{2A}R does not exhibit this degradation during expression. Previous studies expressing the WT A_{2A}R in *E. coli* demonstrated C-terminal degradation upon solubilisation [22]. In addition, work in our group has shown C-terminal degradation of the WT A_{2A}R expressed in *P. pastoris* upon purification to high homogeneity (Singh et al, manuscript in preparation). These data indicate an intrinsic instability in the WT A_{2A}R. This degradation has not been previously reported for expression of the receptor in relatively small scale *P. pastoris* cultures [16] and this is supported by the findings of this study since no degradation bands were observed for either construct in flask cultures. It may be that the very high expression levels achieved in the bioreactor reduces the processing and targeting time of the receptor making it more vulnerable to degradation by intracellular proteases. The lack of degradation of the V334 A_{2A}R indicates that this is more stable and therefore a more suitable candidate for further downstream structural and functional studies. Recent work by Magnani et al, [31] describes the identification of a number of mutants of the human A_{2A}R with increased thermostability and increased stability in short chain detergents making them more suitable for crystallisation. Mutant screening was performed in *E. coli*, however it may be that the use of a eukaryotic system like the large-scale *P. pastoris* system described in this manuscript is more suitable for the production of the mutant receptors for structural studies.

Conclusion

The use of *P. pastoris* bioreactor cultures has significant advantages over traditional flask cultures for the expression of GPCRs for functional and structural studies. Bioreactors yield higher cell densities as well as higher levels of functional A_{2A}R per mg of membrane protein compared to flask cultures. Greater control of both cell growth and induction conditions allow much greater reproducibility of receptor expression. This study has also identified a more stable truncated V334 A_{2A}R construct for further functional and structural studies.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SS and PGS carried out all the radioligand binding assays, SS, AG, CF-V and MM optimised the bioreactor running conditions, AG, CF-V and MM performed the flask cultures for comparison, RR, MM and AG optimised the Western blots, RW and JR made the expression constructs while RW developed the flask expression conditions, BB designed the research and wrote the manuscript.

Acknowledgements

We thank James Mansfield for technical assistance. This research was funded by the Biological and Biophysical Research Council, the Membrane Protein Network (MePNet), the European Membrane Protein Consortium (E-MeP), and the French government (Association Nationale de la Recherche Technique).

References

- Hopkins AL, Groom CR: **The druggable genome.** *Nat Rev Drug Discov* 2002, **1**:727-30.
- Klabunde T, Hessler G: **Drug design strategies for targeting G-protein-coupled receptors.** *Chembiochem* 2002, **3**:928-44.
- Tate CG, Grishammer R: **Heterologous expression of G-protein-coupled receptors.** *Trends Biotechnol* 1996, **14**:426-30.
- Chelikani P, Reeves PJ, Rajbhandary UL, Khorana HG: **The synthesis and high-level expression of a beta2-adrenergic receptor gene in a tetracycline-inducible stable mammalian cell line.** *Protein Sci* 2006, **15**:1433-40.
- Lundstrom K, Wagner R, Reinhart C, Desmyter A, Cherouati N, Magnin T, Zeder-Lutz G, Courtot M, Prual C, André N, Hassaine G, Michel H, Cambillau C, Pattus F: **Structural genomics on membrane proteins: comparison of more than 100 GPCRs in 3 expression systems.** *J Struct Funct Genomics* 2006, **7**:77-91.
- Long SB, Campbell EB, Mackinnon R: **Crystal structure of a mammalian voltage-dependent Shaker family K⁺ channel.** *Science* 2005, **309**:897-903.
- Cregg JM, Vedvick TS, Raschke WC: **Recent advances in the expression of foreign genes in *Pichia pastoris*.** *Biotechnology (N Y)* 1993, **11**:905-10.
- Sreekrishna K, Brankamp RG, Kropp KE, Blankenship DT, Tsay JT, Smith PL, Wierschke JD, Subramaniam A, Birkenberger LA: **Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast *Pichia pastoris*.** *Gene* 1997, **190**:55-62.
- Reiländer H, Weiss HM: **Production of G-protein-coupled receptors in yeast.** *Curr Opin Biotechnol* 1998, **9**:510-7.
- Cereghino JL, Cregg JM: **Heterologous protein expression in the methylotrophic yeast *Pichia pastoris*.** *FEMS Microbiol Rev* 2000, **24**:45-66.
- Weiss HM, Haase W, Michel H, Reiländer H: **Expression of functional mouse 5-HT_{5A} serotonin receptor in the methylotrophic yeast *Pichia pastoris*: pharmacological characterization and localization.** *FEBS Lett* 1995, **377**:451-6.
- Weiss HM, Haase W, Michel H, Reiländer H: **Comparative biochemical and pharmacological characterization of the mouse 5HT_{5A} 5-hydroxytryptamine receptor and the human beta2-adrenergic receptor produced in the methylotrophic yeast *Pichia pastoris*.** *Biochem J* 1998, **330**(Pt 3):1137-1147.
- de Jong LA, Grünwald S, Franke JP, Uges DR, Bischoff R: **Purification and characterization of the recombinant human dopamine D_{2S} receptor from *Pichia pastoris*.** *Protein Expr Purif* 2004, **33**:176-84.
- Sarramegna V, Muller I, Mousseau G, Froment C, Monsarrat B, Milon A, Talmont F: **Solubilization, purification, and mass spectrometry analysis of the human mu-opioid receptor expressed in *Pichia pastoris*.** *Protein Expr Purif* 2005, **43**:85-93.
- André N, Cherouati N, Prual C, Steffan T, Zeder-Lutz G, Magnin T, Pattus F, Michel H, Wagner R, Reinhart C: **Enhancing functional production of G protein-coupled receptors in *Pichia pastoris* to levels required for structural studies via a single expression screen.** *Protein Sci* 2006, **15**:1115-26.
- Fraser NJ: **Expression and functional purification of a glycosylation deficient version of the human adenosine 2a receptor for structural studies.** *Protein Expr Purif* 2006, **49**:129-37.
- Murata Y, Watanabe T, Sato M, Momose Y, Nakahara T, Oka S, Iwashashi H: **Dimethyl sulfoxide exposure facilitates phospholipid biosynthesis and cellular membrane proliferation in yeast cells.** *J Biol Chem* 2003, **278**:33185-93.
- Cereghino GP, Cereghino JL, Ilgen C, Cregg JM: **Production of recombinant proteins in fermenter cultures of the yeast *Pichia pastoris*.** *Curr Opin Biotechnol* 2002, **13**:329-32.

19. Zhang W, Smith LA, Plantz BA, Schlegel VL, Meagher MM: **Design of methanol feed control in *Pichia pastoris* fermentations based upon a growth model.** *Biotechnol Prog* 2002, **18**:1392-9.
20. Mattanovich D, Gasser B, Hohenblum H, Sauer M: **Stress in recombinant protein producing yeasts.** *J Biotechnol* 2004, **113**:121-35.
21. Linden J: **Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.** *Annu Rev Pharmacol Toxicol* 2001, **41**:775-787.
22. Weiss HM, Grishammer R: **Purification and characterization of the human adenosine A(2a) receptor functionally expressed in *Escherichia coli*.** *Eur J Biochem* 2002, **269**:82-92.
23. O'Malley MA, Lazarova T, Britton ZT, Robinson AS: **High-level expression in *Saccharomyces cerevisiae* enables isolation and spectroscopic characterization of functional human adenosine A2a receptor.** *J Struct Biol* 2007, **159**:166-78.
24. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC: **High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.** *Science* 2007, **318**:1258-65.
25. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF: **Structure of a beta1-adrenergic G-protein-coupled receptor.** *Nature* 2008, **454**:486-91.
26. Lowry OH, Rosebrogh NJ, Farr AL, Randall RJ: **Protein measurement with the Folin phenol reagent.** *J Biol Chem* 1951, **193**:265-75.
27. Guarna MM, Lesnicki GJ, Tam BM, Robinson J, Radziminski CZ, Hasenwinkle D, Boraston A, Jervis E, Macgillivray RT, Turner RF, Kilburn DG: **On-line monitoring and control of methanol concentration in shake-flask cultures of *Pichia pastoris*.** *Biotechnol Bioeng* 1997, **56**:279-86.
28. Saïda F, Uzan M, Odaert B, Bontems F: **Expression of highly toxic genes in *E. coli*: special strategies and genetic tools.** *Curr Protein Pept Sci* 2006, **7**:47-56.
29. Tschopp JF, Brust PF, Cregg JM, Stillman CA, Gingeras TR: **Expression of the lacZ gene from two methanol-regulated promoters in *Pichia pastoris*.** *Nucleic Acids Res* 1987, **15**:3859-76.
30. Hassaine G, Wagner R, Kempf J, Cherouati N, Hassaine N, Prual C, André N, Reinhart C, Pattus F, Lundstrom K: **Semliki Forest virus vectors for overexpression of 101 G protein-coupled receptors in mammalian host cells.** *Protein Expr Purif* 2006, **45**:343-51.
31. Magnani F, Shibata Y, Serrano-Vega MJ, Tate CG: **Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor.** *Proc Natl Acad Sci USA* 2008, **105**:10744-9.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

